1. India Stocks

  2. •

    Consumer Cyclical

  3. •

    Packaging & Containers
Bilcare Limited

Bilcare Limited

BI.BO
Bilcare LimitedIN flagBombay Stock Exchange
62.15
INR
+1.69
- -
1.46BMarket Cap
Bilcare Limited
BI.BO
(Bombay Stock Exchange)

Recent

price

62.15

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
971.14
1,546.72
1,506.35
1,300.47
1,143.46
1,103.86
1,118.24
1,177.53
1,270.25
773.73
260.96
353.78
409.7
313.59
336.23
- -
311.95
Revenue per Share
62.65
58
16.82
-48.14
-91.76
-36.04
-35.9
-85.43
-193.28
-43.97
-8.95
-5.35
6.39
-14.11
-0.32
- -
-3.69
Basic EPS, GAAP
-289.8
-130.18
-342.7
-66.96
-133.85
-10.12
65.89
-49.25
38.33
108.8
27.93
15.53
-268.68
-24.32
27.24
- -
- -
Free Cash Flow per Basic Share
2.81
3.49
2.32
- -
- -
0.49
0.49
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
194.86
226.43
190.92
142.79
-15.22
-43.66
-80.21
-172.9
-374.52
-250.5
-259.51
-248.51
-193.46
-88.12
-100.91
- -
10.02
Book Value per Share
396.1
474.91
465.44
439.4
212.09
149.62
125.65
17.41
-173.24
64.08
62.91
63.09
290.42
266.09
244.1
- -
28.27
Tangible Book Value per Share
24
24
24
24
24
24
24
24
24
24
24
24
24
24
23
- -
24
Basic Weighted Avg Shares
22,866
36,418
35,467
30,620
26,923
25,991
26,329
27,725
29,908
18,218
6,144
8,330
9,646
7,384
7,880
7,335
7,335
Sales/Revenue/Turnover
10.43
10.02
7.53
3.34
-0.2
2.69
0.58
-8.11
-6.97
-10.51
1.4
2.54
2.05
-0.52
-0.04
3.36
0.54
Operating Margin (%)
9,095
1,998
1,485
3,229
32
1,636
1,769
4,162
3,784
2,388
455
393
378
449
181
198
405
Depreciation Expense
1,475
1,366
396
-1,133
-2,160
-849
-845
-2,011
-4,551
-1,035
-211
-126
150
-332
-8
17
-87
Net Income, GAAP
24.99
25.69
24.75
- -
- -
- -
- -
- -
- -
- -
- -
- -
74.39
- -
- -
- -
- -
Effective Tax Rate (%)
6.45
3.75
1.12
-3.7
-8.02
-3.26
-3.21
-7.25
-15.22
-5.68
-3.43
-1.51
1.56
-4.5
-0.1
0.23
-1.18
Profit Margin (%)
9,536
13,349
10,223
10,582
4,002
1,487
432
-10,453
-11,870
540
239
180
46
611
38
612
612
Working Capital
11,997
13,032
17,695
18,817
17,532
18,926
18,012
7,410
7,454
5,588
5,299
5,369
5,157
5,454
4,634
4,600
4,600
LT Debt
11,147
13,867
13,790
13,764
7,940
7,716
6,760
4,633
-58
1,762
1,642
1,613
7,040
6,462
5,898
741
741
Total Equity
9.4
10.64
6.43
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.46
- -
- -
- -
- -
Return on Invested Capital (%)
16.55
11.9
5.66
- -
- -
- -
- -
- -
- -
- -
- -
- -
-2.01
- -
- -
- -
- -
Return on Capital (%)
35.29
27.53
8.06
-28.85
- -
- -
- -
- -
- -
- -
- -
- -
- -
-141.1
- -
- -
-24.12
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
2,078
- -
1,604
LT Borrowings
4,530
- -
4,497
LT Finance Leases
112
- -
103
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
24
- -
24
Market Capitalization
1,937
1,873
1,241

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
3,934
- -
3,533
Cash, Cash Equivalents & STI
928
- -
525
Accounts Receivable, Net
1,170
- -
1,080
Inventories
1,067
- -
1,148
Total Current Liabilities
3,401
- -
2,922
Payables & Accruals
- -
- -
- -
ST Debt
2,078
- -
1,604
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-305.26%
46.06%
-87.43%
Free Cash Flow
-308.77%
-418.76%
83.21%
Net Income, GAAP
-90.08%
-201.54%
-329.33%
Sales/Revenue/Turnover
-6.32%
5.55%
-6.92%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,822
1,899
1,749
1,904
7,384
2025
1,941
2,017
1,981
1,940
7,880
2026
1,864
1,782
1,813
1,877
7,335

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-3.36
-3.22
-2.91
- -
-14.11
2025
-2.71
-6.81
-3.05
7.47
-0.32
2026
-1.59
-5.25
-2.53
5.68
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
TFF Group (TFF.PA)
K Laser Technology Inc. (2461.TW)
Jiamei Food Packaging (Chuzhou) Co.,Ltd (002969.SZ)
Thong Guan Industries Berhad (7034.KL)
HySum Flexibles Global, Inc. (300501.SZ)
Promact Impex Limited (PROMACT.BO)
Business
Bilcare Limited (BI.BO), founded in 1987 and headquartered in Pune, India, operates as a holding company providing pharmaceutical packaging research solutions, global clinical services, research and development services, and anti-counterfeit technologies to the global pharmaceutical industry; its core products and services include specialty polymer films such as blister films, laminates, high-barrier products like Ultra Tx and Armour, and eco-friendly options like Optra; aluminum foils encompassing child-resistant (CR) foils, lidding foils, and blister foils; clinical trial supply management featuring manufacturing and packaging of investigational medicinal products (IMPs) and placebos, primary and secondary packaging with blinding techniques, interactive web response systems (IWRS), worldwide distribution, returns, and destructions; and R&D offerings such as formulation stability studies, blister/foil design and development, analytical research, packaging trials, pharmaceutical brand innovation, and market studies. The company serves pharmaceutical manufacturers worldwide across over 100 countries, with manufacturing facilities in Pune and Nashik boasting 50,000 tonnes annual capacity, ISO Class 8 clean rooms, and compliance with global standards including USFDA, EU Pharmacopoeia, USP 661.1, REACH, and DMF filings; it emphasizes its novel 5Cs approach—Convenience, Communication, Compliance, Child-Resistant, and Counterfeiting protection—delivered through barrier properties against moisture/light/gases, high-speed machinability, printability, and embedded security features. In March 2023, Bilcare completed a major strategic shift by transferring its pharmaceutical packaging innovation (PPI) business to Caprihans India Limited via a slump sale for Rs 213 crore in redeemable preference shares, enabling the company to become debt-free, reduce overheads, and refocus on high-growth areas including global clinical supplies, R&D services, and anti-counterfeit solutions like nonClonableID (nCID) technologies; this consolidation enhances synergies within the group while positioning Bilcare for improved profitability and global expansion in clinical services.